Origin Agritech shares surge 10.62% intraday after appointing biotech expert Dr. Jian Zhang to board and rehiring CFO Dr. Zheng James Chen.

Origin Agritech surged 10.62% intraday following the announcement of strategic leadership changes, including the appointment of Dr. Jian Zhang—a veteran biotech executive with deep experience in crop biotechnology and regulatory affairs—as an independent board member, and the reappointment of Dr. Zheng James Chen as CFO. The moves underscore the company’s commitment to advancing its GMO seed pipeline, with Zhang’s expertise in transgenic crop development and regulatory compliance directly addressing technical and commercialization challenges, while Chen’s return brings institutional financial acumen and continuity. These appointments signal enhanced governance and operational credibility, aligning with Origin’s focus on scaling its biotech commercialization efforts in China. The leadership reshaping, coupled with Zhang’s track record at DuPont Pioneer and Syngenta and Chen’s prior roles at Origin and Abu Dhabi Investment Authority, likely bolstered investor confidence in the company’s ability to navigate regulatory hurdles and execute its long-term growth strategy.